Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO and Cyclosporin A in Refractory ITP
NCT02203422Phase 3Withdrawn
- Sponsor
- Shandong University
- Start
- Jul 2014
- Primary completion
- Jul 2015
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human thrombopoietin in immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoints: Evaluation of platelet response (Complete Response) at 3 months, Evaluation of platelet response (Response) at 3 months and 2 more. Planned start Jul 2014; status: withdrawn.
02
Drugs
recombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02203422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203422.